BACHEM HOLDING AG
Bubendorf/Basel, August 25, 2014 - Bachem (SIX: BANB) announced today that Dr. Günther Loidl will succeed Dr. Daniel Erne as Chief Technology Officer of Bachem Group on January 1, 2015. Dr. Daniel Erne officially retires on that date yet will continue to serve the company in an advisory capacity.
Dr. Günther Loidl was born in Germany in 1970 and studied chemistry in Regensburg (Germany) and Leeds (UK). After obtaining his doctorate under the supervision of Prof. Dr. Luis Moroder at the Max Planck Institute of Biochemistry in Martinsried (Germany), he joined Bachem AG in 2000 and headed a unit in the Research and Development (R&D) department from 2002 to 2009. Afterwards he gathered experience in large-scale GMP production as head of active substance manufacturing for New Chemical Entities and generics. He has served as Head of R&D at the company's headquarters in Bubendorf and as a member of the local management team since 2012. Dr. Günther Loidl is married and the father of two daughters.
Dr. Kuno Sommer, Chairman of Bachem's Board of Directors: "We are delighted to have found a distinguished and competent successor for Daniel Erne in the person of Günther Loidl. He will take over a challenging and exciting dossier from his predecessor. Thanks to his many years of service with Bachem, Günther already possesses the necessary understanding and knowledge of our core business of peptides as well as of our customers, projects and technologies to take on this new position. We thank Daniel Erne for his valuable services to the company over the course of 27 years, during which time he held various positions and helped to shape our successful corporate development. We wish him well for the future and we wish his successor Günther Loidl a good start and much success as Chief Technology Officer at Bachem."
Bachem is a listed technology-based company focused on peptide chemistry. The company provides a full range of services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients. A comprehensive catalog of biochemicals and exclusive custom syntheses for research
labs complete the service portfolio. Headquartered in Switzerland with subsidiaries in
Europe and the US, the group has a global reach with more experience and know- how than any other company in the industry. Towards its customers, Bachem shows total commitment to quality, innovation and partnership.
Fax: +41 61 935 2324 www.bachem.com ir@bachem.com
|
distributed by
|
